Enlightify Inc. (ENFY): Nasdaq/NYSE listing notice — China Green Agriculture receives NYSE delisting notice for late Form 10-Q; six-month cure period

Enlightify Inc.

NYSE notice on Nov 22, 2022 for failure to file Form 10-Q for quarter ended Sep 30, 2022 due to COVID-19 restrictions in China.
Stock to trade under symbol CGA with 'LF' indicator until filing is completed.
Company has six months from the filing due date to file and regain compliance; NYSE may grant up to an additional six months.
If not filed within cure period, suspension and delisting procedures may commence.
Company states it is working diligently with its accounting firm to complete the filing.

item 3.01 item 8.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.95

Enlightify Inc. received a nyse noncompliance notice notice regarding late filing (rules 802.01E).

Exchange: nyse
Notice: noncompliance notice
Deficiency: late filing
Rules: 802.01E

Exact text from the filing

November 22, 2022, China Green Agriculture, Inc. (the “Company”) received a notice from the New York Stock Exchange (the “NYSE”) indicating that the Company is not in compliance with the NYSE’s continued listing requirements under the timely filing criteria established in Section 802.01E of the NYSE Listed Company Manual as a result of its failure to timely file its Quarterly Report on Form 10-Q for the period ended September 30, 2022 (the “Form 10-Q”). As reported by the Company in its Form 12b-25 filed with the Securities and Exchange Commission (the “SEC”) on November 15, 2022, the Company

View on SEC.gov

Browse all listing & compliance notices →

Enlightify Inc. filing history →

Source: SEC EDGAR

accession 0001213900-22-076434

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.